BioCentury | Sep 23, 2020
Management Tracks

Gilead BD head Bender takes top job at pediatric cancer start-up Day One

...VP of BD; and Vai Lee, who held clinical operations roles at Acerta Pharma B.V., Diablo...
BioCentury | Sep 11, 2017
Distillery Therapeutics

Cancer

...INDICATION: Sarcoma Mouse studies suggest combining DIABLO mimetics with an oncolytic vesicular stomatitis virus (VSV) could...
...VSV) could help treat rhabdomyosarcoma. In an orthotopic xenograft mouse model of the cancer, the DIABLO...
...I testing for head and neck cancer, liver cancer and solid tumors. TARGET/MARKER/PATHWAY: Diablo homolog (DIABLO; SMAC...
BioCentury | Jul 21, 2017
Clinical News

Debiopharm completes enrollment in Phase I/II of Debio 1143 for SCCHN

...inhibitor of apoptosis (IAP) antagonist that mimics the activity of second mitochondrial-derived activator of caspases (SMAC...
BioCentury | Jul 10, 2017
Distillery Therapeutics

Cancer

...The compound consisted of an androgen receptor ligand and a peptidomimetic of the IAP ligand DIABLO...
...Phase II testing for liver cancer. TARGET/MARKER/PATHWAY: Androgen receptor; inhibitor of apoptosis (IAP); diablo homolog (DIABLO; SMAC...
...National Institute of Health Sciences, Tokyo, Japan email: miki-naito@nihs.go.jp Karen Tkach Tuzman Casodex National Institute of Health Sciences Androgen receptor Diablo homolog (DIABLO) (SMAC) E3...
BioCentury | Nov 3, 2016
Company News

TetraLogic, Medivir deal

...trial for the indication in 2H17. Birinapant is a small molecule peptidomimetic of diablo homolog (DIABLO; SMAC...
...Medivir AB (SSE:MVIR B), Huddinge, Sweden Business: Cancer Alicia Parker birinapant Suberohydroxamic acid phenyl ester (SHAPE) Medivir AB TetraLogic Pharmaceuticals Corp. Diablo homolog (DIABLO) (SMAC) Histone...
BioCentury | Oct 24, 2016
Company News

NBE-Therapeutics, Sotio deal

...ADCs) against undisclosed targets to treat cancer. The collaboration will use NBE’s Transpo-mAb antibody platform, SMAC...
BioCentury | Jun 13, 2016
Clinical News

AT-406: Phase II started

...of apoptosis (IAP) antagonist that mimics the activity of second mitochondrial-derived activator of caspases ( SMAC...
BioCentury | Feb 1, 2016
Clinical News

Birinapant: Phase II discontinued

...Business: Cancer Molecular target: Inhibitor of apoptosis (IAP) Description: Small molecule peptidomimetic of diablo homolog (DIABLO; SMAC...
BioCentury | Jul 27, 2015
Clinical News

Birinapant: Preliminary Phase IIa data

...Business: Cancer Molecular target: Inhibitor of apoptosis (IAP) Description: Small molecule peptidomimetic of diablo homolog (DIABLO; SMAC...
BioCentury | May 25, 2015
Clinical News

Birinapant: Phase Ib/IIa halted

...Business: Infectious Molecular target: Inhibitor of apoptosis (IAP) Description: Small molecule peptidomimetic of diablo homolog (DIABLO; SMAC...
Items per page:
1 - 10 of 38